Medtronic

heart data research doctor cardiologist AI

A significant risk in female heart patients: Paradoxical low-flow, low-gradient AS

Identifying the signs of severe aortic stenosis is typically a fairly straightforward process for cardiologists. In some cases, however, the patient’s symptoms present in a way that is outside of the norm. 

doctor patient elderly check up hospital

Prosthesis-patient mismatch after TAVR: Key details cardiologists need to know

Prosthesis-patient mismatch (PPM) is the phenomenon that occurs when the effective orifice area of a prosthetic heart valve isn’t adequately sized to meet a patient’s blood flow requirements. More is known today about PPM than ever before—but there is still so much to learn. 

Doctor with patient

A new era of electrophysiology: Accelerating innovation for AFib with pulsed field ablation

Atrial fibrillation (AFib), the most common heart rhythm disorder, continues to rise globally - it is predicted to affect more than 12 million people in the US by 2030 and almost 18 million people in Europe by 2060. With a growing aging population and an increased prevalence of heart disease, the demand for effective treatments for AFib is higher than ever before. 

medtronic_webinar_teaser.png

TAVR for Today’s Patient: Updates on Data, Risk, Anatomy, and Access

Listen in as a general cardiologist, surgeon, and interventionalist delve into the latest evidence—including the Evolut™ TAVR 5-Year Low Risk data and SMART Trial 2-Year update—to guide appropriate treatment decisions for patients with severe symptomatic aortic stenosis.

Michael Reardon, MD, explained the low-risk Evolut 5-year results of TAVR vs. SAVR at ACC 2025. #ACC #ACC25 #ACC2025

5-year Evolut Low Risk Data: Durable clinical outcomes, outstanding valve performance

The late-breaking five-year results of the Evolut Low-Risk Trial presented at ACC.25 showed positive results for the Evolut TAVR system when compared to SAVR.

Howard Herrmann, MD, University of Pennsylvania, explains details of the SMART Trial 2-year results at CRT 2025, where Evolut performed better hemodynamically than the Sapien 3 TAVR valve in small annuli patients. The study included 87% women.

SMART 2-year TAVR hemodynamic data: Medtronic Evolut is better compared to Edwards Sapien in small annulus patients

Howard Herrmann, MD,  MSCAI, Hospital of the University of Pennsylvania, and lead invesigator for the SMART trial, explains details on the 2-year data comparing the Evolut vs. Sapien 3 for TAVR in small annulus patients.

FX+ Image

Physicians are leaning into supra-annular, self-expanding TAVR valves for women and small-annulus patients

"The onus is on us as cardiologists to make sure we offer the very best possible devices for our patients with the available data that we have," interventional cardiologist Anene Ukaigwe, MD, explained. 

doctorwithpatient.jpg

Women with severe aortic stenosis remain underdiagnosed, undertreated—here’s how cardiologists can make a difference

Women with cardiovascular disease are consistently underdiagnosed and undertreated compared to men, and those disparities are true for aortic stenosis as well. Women with symptomatic severe AS are up to 35% less likely than men to undergo aortic valve replacement, for example, and they often have to wait longer just to be referred for further care.